DNA Vaccine Targets 40 Tumor Proteins, Keeps Two-Thirds of Glioblastoma Patients Recurrence-Free
Updated
Updated · Blackchronicle · Jul 4
DNA Vaccine Targets 40 Tumor Proteins, Keeps Two-Thirds of Glioblastoma Patients Recurrence-Free
3 articles · Updated · Blackchronicle · Jul 4
Summary
Two-thirds of glioblastoma patients in a clinical trial were recurrence-free six months after surgery following treatment with a personalized DNA vaccine, according to a Nature Cancer study.
The vaccine was designed to target up to 40 proteins unique to each patient’s tumor, helping expose glioblastoma cells that often remain hidden from the immune system.
Researchers said that immune targeting translated into significantly longer survival for patients with the aggressive brain cancer, pointing to a more individualized treatment approach.
Will a new DNA vaccine become a real cure for brain cancer, or is it just hope for a select few?
Could your smartwatch soon detect Alzheimer's risk by tracking your brain's nightly waste clearance?
Personalized Neoantigen DNA Vaccine GNOS-PV01 Demonstrates Encouraging Phase 1 Outcomes in Glioblastoma
Overview
GNOS-PV01, a personalized DNA vaccine, has shown promising early results in a Phase 1 clinical trial for glioblastoma. The trial involved nine patients and focused on assessing the vaccine’s safety and its ability to generate an immune response. Researchers observed that GNOS-PV01 successfully met its pre-set goals, producing real immune signals and stimulating the body’s immune system to target cancer cells. Notably, one patient remained alive four years after treatment, which is rare for this disease. These encouraging early findings highlight the potential of GNOS-PV01 as a new hope for patients with aggressive brain cancer.